BioSpace News Archive

As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” session focused on the need to expedite more bespoke gene editing treatments like the one that saved young KJ Muldoon.

Trained biostatisticians play a central role in clinical science and public health. Brown’s online master’s in biostatistics (health data science concentration), prepares you with a strong foundation in biostatistical and data science methods combined with rigorous training in applied skills to make critical data-driven decisions and meet the growing demand for leaders in this industry – on your schedule

George Church’s Rejuvenate Bio is turning to social networks to help fund its work on one-time gene therapies targeting chronic diseases and root causes of aging.

After striking a Most Favored Nation deal with the White House in January, Johnson & Johnson will now offer Xarelto at 68% off on TrumpRx, dropping its price from $611.82 to $197 per 30-pill pack.

FDA inspectors warned UCSF radiopharmaceutical facility that losing environmental control could pose a serious hazard to patients.

With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for hereditary angioedema.

Eli Lilly is picking up Ajax Therapeutics and its once-daily oral blood cancer candidate. The deal follows the pharma’s buyouts of ADC specialist CrossBridge Bio and in vivo CAR T company Kelonia Therapeutics.

Sun Pharmaceutical is bringing Merck spinoff Organon into the fold, paying $11.75 billion in hopes of becoming a top global biosimilar player.

While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.